A digital platform that uses artificial intelligence for chronic disease clinical decision support is bringing a new model of care to cardiac patients in rural areas.
An innovative, Australian-developed device for the treatment of perforated eardrums has the potential to improve thousands of lives.
What began as an ideas incubator for the South Australian medtech sector has expanded nationally - setting a new benchmark for the translation of medical device technology in Australia.
Artificial Intelligence (AI) is changing the face of healthcare, and Artrya wants to redefine how the risk of heart disease is detected in patients.
The Trial Ready Registry Framework (TRRF) project co-funded by MTPConnect Project Fund Program and Queensland University of Technology (QUT), set out to develop a single digital trial ready registry platform to better collect and analyse health data.
In 2019, Anatomics saw an opportunity to turn an abandoned car manufacturing facility in Melbourne into an expansive 3D bioprinting warehouse.
OncoRes Medical was founded at the intersection of medicine, science and humanity by leading clinicians and researchers from the University of Western Australia, the Harry Perkins Institute of Medical Research, and the Western Australian Department of Health.
Noisy Guts is an emerging early-stage WA medtech start-up that has been awarded $1 million matched funding in Round 1 of MTPConnec's Biomedical Translation Bridge Program.
According to research from Arthritis Australia, the number of people with osteoarthritis and damaged cartilage in Australia is expected to increase nationally from almost 2.2 million in 2015 to almost 3.1 million Australians in 2030.
A clinical manufacturing training hub set up by The Translational Research Institute (TRI), in collaboration with VAXXAS, PharmOut & Eurofins AMS is enabling the translation of innovative, investigational products into clinical studies.
Microscopy Australia, through the MTPConnect Project Fund Program, set out to provide easy and discounted access to its microscopy services for medtech R&D companies, by funding up to 200 technical vouchers to reduce existing barriers to use.
The Clinical Oncology Society of Australia (COSA) are bringing access to clinical trials for patients living in rural areas, with support from a funding consortium of industry, Medicines Australia, research institutes and consumer groups.
International markets can be difficult to access for Australian MTP sector companies, with a number of challenges to entry. As part of the MTPConnect Project Fund Program, an Asialink Business project commenced in 2019 to identify opportunities for Australian companies to access global markets.
The National Biologics Training Program - born out of The University of Queensland - has set up an international collaboration with Thailand's Centre of Excellence for Life Sciences (TCELS) to provide its biopharmaceutical researchers with professional development training to strengthen capabilities in Biologics R&D, advanced biomanufacturing and global regulation.
Australia has a strong and flourishing clinical trials environment, which makes it an attractive destination to conduct trials.